Cargando…

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC

INTRODUCTION: Durvalumab consolidation therapy is the standard of care after concurrent chemoradiotherapy (CRT) for stage III NSCLC. Immune-related pneumonitis during durvalumab treatment is potentially fatal; however, information is lacking regarding the impact of pneumonitis on patient survival. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kinehara, Yuhei, Shiroyama, Takayuki, Tamiya, Akihiro, Tamiya, Motohiro, Minami, Seigo, Kanazu, Masaki, Morimura, Osamu, Niki, Toshie, Tetsumoto, Satoshi, Taniguchi, Yoshihiko, Kuge, Tomoki, Nishino, Kazumi, Nagatomo, Izumi, Kumanogoh, Atsushi, Tachibana, Isao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679942/ https://www.ncbi.nlm.nih.gov/pubmed/38029024 http://dx.doi.org/10.1016/j.jtocrr.2023.100586

Ejemplares similares

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Favorable response to pembrolizumab after durvalumab failure in a stage III sarcomatoid carcinoma of the lung: a case report
por: Nishino, Kazumi, et al.
Publicado: (2020)

Cytokine Release Syndrome and Immune-Related Pneumonitis Associated With Tumor Progression in a Pulmonary Pleomorphic Carcinoma Treated With Nivolumab Plus Ipilimumab Treatment: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2021)

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer
por: Kaneda, Toshihiko, et al.
Publicado: (2018)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021)

Durvalumab: Immune-related pneumonitis: case report
Publicado: (2021)

Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
por: Diamond, Brett H., et al.
Publicado: (2022)

Afatinib-induced severe esophagitis in a lung cancer patient with an activated epidermal growth factor receptor mutation: A case report
por: Inoue, Takako, et al.
Publicado: (2017)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis
por: Naito, Yujiro, et al.
Publicado: (2017)

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
por: Kanazu, Masaki, et al.
Publicado: (2020)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
por: Tonk, Erwin H.J., et al.
Publicado: (2019)

Pembrolizumab-induced acute thrombosis: A case report
por: Kunimasa, Kei, et al.
Publicado: (2018)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
por: Kunimasa, Kei, et al.
Publicado: (2021)

Immunochemotherapy Disrupts Peripherally Located Lung Squamous Cell Carcinoma Resulting in Pleuritis: A Report of Two Cases, Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
por: Shaverdian, Narek, et al.
Publicado: (2020)

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
por: Shiroyama, Takayuki, et al.
Publicado: (2017)

Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab
por: Ninomiya, Ryusuke, et al.
Publicado: (2022)

Metastatic Lung Tumors from Colorectal Cancer with EGFR Mutations That Responded to Osimertinib
por: Yanagisawa, Atsushi, et al.
Publicado: (2022)

Pulmonary metastases of lung adenocarcinoma mimicking COVID-19 pneumonia
por: Shiroyama, Takayuki, et al.
Publicado: (2020)

Consolidation of the perinatal care system and workload of obstetricians: an ecological study in Japan
por: Hattori, Sanae, et al.
Publicado: (2023)

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
por: Nakao, Keiko, et al.
Publicado: (2019)

Exploratory analysis to predict pneumonitis during durvalumab consolidation therapy for patients with locally advanced non‐small cell lung cancer from proteomic profiling of circulating extracellular vesicles
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan
por: Oshiro, Yoshiko, et al.
Publicado: (2021)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis
por: Huang, Sherri, et al.
Publicado: (2022)

Lateral Decubitus Position Enables Further Advancement of the Bronchoscope into the Lung Periphery
por: Miyake, Kotaro, et al.
Publicado: (2022)

Secondary subcutaneous abscess due to mixed infections by Peptoniphilus olsenii and Gleimia europaea after COVID‐19
por: Yamamoto, Yuji, et al.
Publicado: (2023)

Infectious pericarditis caused by Gemella sanguinis induced by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA): A case report
por: Inoue, Takako, et al.
Publicado: (2020)

Manual route modification using an oblique method following automatic virtual bronchoscopic navigation
por: Inoue, Takako, et al.
Publicado: (2022)

Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma: A case report
por: Matsumoto, Kinnosuke, et al.
Publicado: (2022)

Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies
por: Matsumoto, Kinnosuke, et al.
Publicado: (2022)

Respiratory Impedance is Associated with Ventilation and Diffusing Capacity in Patients with Idiopathic Pulmonary Fibrosis Combined with Emphysema
por: Yamamoto, Yuji, et al.
Publicado: (2022)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
por: Langberg, Christian Wilhelm, et al.
Publicado: (2023)

Rapid and reliable collection of tumor tissue for successful gene panel in a patient with advanced stage lung cancer: A case report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vpd1d1s6pl9dlgqiabvfhh8idk